TD Cowen analyst Marc Frahm has maintained their bullish stance on CGEM stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Marc Frahm has given his Buy rating due to a combination of factors related to Cullinan Management’s promising pipeline and financial stability. The company reported a significant cash reserve of $511 million, which is expected to sustain operations into 2028, providing a strong financial foundation for ongoing and future projects.
Furthermore, Cullinan’s key asset, CLN-978, is advancing well in its clinical trials for autoimmune diseases, with data expected in the first half of 2026. Additionally, CLN-049 has shown competitive efficacy in treating AML, with promising response rates that suggest potential for broader applicability. These developments, along with the progress of Zipalertinib towards regulatory approval, underpin the positive outlook and justify the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CGEM in relation to earlier this year.